To update the 2004 American Academy of Neurology (AAN) guideline for managing treatment-resistant (TR) epilepsy with second-and third-generation antiepileptic drugs (AEDs). Methods: 2004 criteria were used to systematically review literature (January 2003 to November 2015, classify pertinent studies according to the therapeutic rating scheme, and link recommendations to evidence strength. Results: Forty-two articles were included. Recommendations: The following are established as effective to reduce seizure frequency (Level A): immediate-release pregabalin and perampanel for TR adult focal epilepsy (TRAFE); vigabatrin for TRAFE (not first-line treatment; rufinamide for Lennox-Gastuat syndrome (LGS) (add-on therapy).
INTRODUCTION
In 2004, the American Academy of Neurology (AAN) and the American Epilepsy Society (AES) published a guideline on felbamate (FBM) 1 and another guideline on 8 second-generation antiepileptic drugs (AEDs) (table 1 shows principle findings). 2 Since the 2004 publications, the US Food and Drug Administration (FDA) approved 6 new third-generation AEDs and 2 older AEDs (table 2) . This update reviews new evidence for efficacy of these AEDs in managing treatment-resistant (TR) focal epilepsies and generalized epilepsies (GEs) in children and adults. The FDA also approved an additional new drug, brivaracetam, and an additional indication for perampanel (for primary generalized tonic clonic seizures) since the 2004 guideline that are not included in this update. These were excluded since they received FDA approval after the date of the last literature search update in November 2015; per the AAN guideline development process, studies not retrieved in a literature search cannot be included in the systematic review.
A companion guideline update examines the evidence in new-onset focal epilepsy or GE.
This article summarizes the guideline findings, conclusions, and recommendations. The complete guideline, including appendices e-1 through e-6 and tables e-1 through e-6, is available as a data supplement at Neurology.org.
DESCRIPTION OF THE ANALYTIC PROCESS
The AAN and AES convened an expert panel to develop this guideline using the 2004 AAN guideline development process. 3 The complete guideline (data supplement) describes the literature search strategy and evidence review process. Class IV studies are not discussed.
ANALYSIS OF EVIDENCE
For adult patients with TR focal epilepsy, are these AEDs effective as adjunctive therapy in reducing seizure frequency? Pregabalin Pregabalin (PGB) was examined in 2 Class I and 2 Class II studies on immediate-release PGB (PGB-IR) [4] [5] [6] [7] and 1 Class I study of controlled-release PGB (PGB-CR). Abbreviations: AED = antiepileptic drug; CAE = childhood absence epilepsy; IGE = idiopathic generalized epilepsy; LGS = Lennox-Gastaut syndrome.
PGB was significantly superior to placebo at daily doses of 150 mg, 300 mg, and 600 mg, with >50% responder rates and greater median percent seizure reduction, in a dose-related manner. Dizziness and sedation were the most frequently occurring adverse events (AEs) and AE-related drug discontinuation reported, which increased in frequency with higher doses.
A Class I study compared placebo with PGB-CR, 165 and 330 mg/d. e5 The 3 arms failed to differ. AEs and AE-related discontinuation rates were higher in the high-dose arm and similar to the trials with PGB-IR. [6] [7] [8] Conclusions PGB-IR is effective as add-on therapy for TR adult focal epilepsy (TRAFE) (2 Class I studies). Efficacy and AEs increased with higher doses. PGB-CR is probably not effective (1 Class I study).
Clinical context
The initial PGB-IR doses were higher than typically used in clinical practice (25-50 mg/d) and may have led to higher AE occurrence rate. The lack of efficacy of PGB-CR compared with placebo may be due to an exceptionally high placebo responder rate or the failure to use maximal doses (e.g., 600 mg/d).
Lacosamide
Lacosamide (LCM) and placebo were compared in 1 Class I and 2 Class II studies. [9] [10] [11] LCM at doses of 400 and 600 mg/d showed significantly higher responder rates and greater median reduction of seizures than placebo. One Class II study 10 showed 600 mg/d yielded a greater reduction in secondarily generalized tonic-clonic (GTC) seizures. Dose dependent discontinuation because of AEs was not universally observed. AEs were diplopia, vertigo, and emesis in the Class I study 9 and dizziness, nausea, fatigue, ataxia, diplopia, and nystagmus in the Class II studies. 10, 11 A Class III study assessed the parenteral formulation of LCM. 12 Headache, dizziness, and somnolence were the most common AEs, with increased frequency for doses >400 mg/d.
Conclusion
LCM is probably effective in TRAFE (1 Class I study).
Clinical context
Initial LCM doses were higher than typically used in clinical practice (50-100 mg/d) and may have led to a higher AE occurrence rate. Pooled data suggested dizziness was twice as frequent when LCM was used with other sodium channel drugs.
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Rufinamide Rufinamide (RFN) and placebo were compared in 3 Class I studies. [14] [15] [16] RFN was superior to placebo in reduction of median seizure frequency per 28 days and in >50% responder rates; 400 mg/d was the lowest effective dose. Effects were consistently modest.
The most frequent AEs were dizziness, fatigue, nausea, somnolence, diplopia, confusion, ataxia, and impaired concentration.
Conclusion
RFN is effective as add-on therapy for LGS, but benefits are modest (3 Class I studies).
Ezogabine
Ezogabine (EZG) and placebo were compared in 3 Class II studies. [17] [18] [19] EZG at 600, 900, or 1,200 mg/d was superior to placebo for median percent seizure reduction and responder rates.
Treatment-related AEs were dose dependent and included dizziness, somnolence, headache, and fatigue. The most common AEs resulting in discontinuation were dizziness and somnolence. In a Class III study, 20 a significantly higher AE rate occurred with titration rates of <7 days.
Conclusions
EZG is probably effective as add-on therapy for TRAFE (3 Class II studies).
Clinical context
In April 2013, the FDA issued a warning that EZG can cause blue skin discoloration and retina pigment changes, and recommended that any patient taking EZG have baseline and periodic eye examinations. Ezogabine production was discontinued in June 2017.
Vigabatrin
Vigabatrin (VGB) and placebo were assessed in 2 Class I studies. 21, 22 VGB doses at 1, 3, and 6 g/d yielded significantly higher responder rates and median reduction in monthly seizure frequency. Fatigue and drowsiness were the most frequent AEs, with a higher drug discontinuation rate in the 6-mg/d group.
In 1997, 1 study found irreversible retinopathies resulting in bilateral concentric constriction of visual fields associated with higher cumulative doses and increasing age. 23 The FDA requires patients to undergo visual field examinations every 3 months. 
Clinical context
Benefits of VGB should be weighed against the risks, particularly risk of irreversible retinopathy.
Clobazam
Clobazam (CLB) and placebo were assessed in 3 Class III studies, 2 of which had <30 participants, and the larger study included both focal epilepsy and GE. [24] [25] [26] Doses in the larger trial ranged from 10-40 mg/d. 24 Patients randomized to CLB had significantly greater seizure frequency reduction and responder rates. AEs were more frequent with CLB and included sedation, dizziness, irritability, depression, and disinhibition.
Conclusion
CLB is possibly effective as add-on therapy for TRAFE (3 Class III studies). Generalizability may be limited (2 studies had small numbers; the larger study had possibly mixed groups of focal and generalized epilepsy types).
Perampanel
Perampanel (PER) was compared with placebo in 3 Class I studies.
27-29 Dose of 4, 8, and 12 mg/d were superior to placebo in median percent reduction in seizure frequency per 28 days. The dose response rate varied between the studies, perhaps because of a very high placebo rate.
The most common AEs included dizziness, ataxia, falls, headache, somnolence, fatigue, irritability, depression, nausea, and weight gain. AEs were dose related and occurred during both titration and maintenance phases. Irritability and aggressive behavior prompted a package insert warning.
Conclusion

PER is established as effective as add-on therapy in TRAFE (3 Class I studies).
Clinical context
Patients should be monitored closely for the occurrence of psychiatric AEs, in particular irritability and aggressive behavior.
Eslicarbazepine
Eslicarbazepine (ESL) and placebo were compared in 3 studies (1 Class I, 1 Class II, 1 Class III). [30] [31] [32] Single daily doses of 400 mg, 800 mg, and 1,200 mg were investigated. ESL at 800 mg/d and 1,200 mg/d significantly reduced seizure frequency per 4-week period in all 3 studies and yielded significantly higher responder rates in the Class I and III studies. In the Class I study, the seizure-free rate was higher for the 1,200-mg dose.
Treatment-related AEs were generally dose dependent, including those leading to drug discontinuation. The most frequent AEs were dizziness, headache, diplopia, somnolence, nausea, emesis, and coordination difficulties.
Conclusion
ESL doses of 800 and 1,200 mg/d are probably effective in TRAFE (1 Class I study).
Clinical context
The Class I study may have limited generalizability because 100% of patients were Caucasian. Tolerability may have been affected, as >50% of patients were concurrently taking carbamazepine, which is chemically related to ESL.
Extended-release oxcarbazepine
One Class II study compared the extended-release formulation of oxcarbazepine (OXC-XR) with placebo. 33 Significant differences between OXC-XR and placebo were achieved with the 2,400-mg/d dose for responder rates and median percent seizure rate reduction. Placebo rates outside the United States were very high. When only the North American cohort was assessed, the 1,200-mg/d dose was superior to placebo. The most frequent AEs, including those leading to drug discontinuation, were dizziness, ataxic gait, nausea, vomiting, headache, somnolence, fatigue, and diplopia.
Conclusion
OXC-XR 2,400 mg/d is possibly effective for treating TRAFE (1 Class II study).
Extended-release topiramate
A Class I study investigated the extended-release formulation of topiramate (TPM-XR) at 200 mg/d. 34 It was superior to placebo for responder rates and median percent reduction in weekly focal seizures rates. Discontinuation because of AEs was more frequent in patients randomized to TPM-XR; the most frequent AEs were somnolence, paresthesia, and weight loss.
Conclusion
TPM-XR is probably effective as add-on therapy for TRAFE (1 Class I study).
Recommendations
For TRAFE, immediate-release PGB and PER are established as effective to reduce seizure frequency (Level A). Lacosamide, eslicarbazepine, and extended-release topiramate use should also be considered to decrease seizure frequency in this population (Level B). VGB and RFN should be considered established as effective for decreasing seizure frequency in TRAFE (Level A) but are not first-line agents (retinopathy risk with VGB and modest benefit with RFN). Ezogabine use should be considered to decrease seizure frequency in this population (Level B) but carries a serious risk of skin and retinal discoloration. Clobazam and OXC-XR use may be considered to decrease seizure frequency in TRAFE (Level C).
For adult patients with TR focal epilepsy, are these AEDS effective in reducing seizure frequency when used as monotherapy?
In the 2004 guideline, lamotrigine (LTG), OXC (oxcarbazepine), and topiramate (TPM) were found to be effective in TRAFE. Since then, 5 Class III conversion-to-monotherapy studies have been conducted using historical controls. One study evaluated extended-release levetiracetam (LEV-XR), 35 1 evaluated PGB, 36 1 evaluated LCM, 37 and 2 evaluated ESL. 38, 39 In the LEV-XR study, 1,000-mg/d and 2,000-mg/d doses were used. 35 In the PGB study, 150-mg/d and 600-mg/d doses were evaluated. 36 For LCM, 300-mg/d and 400-mg/d doses were compared with historical controls. 37 The ESL studies investigated 1,200-and 1,600-mg/d doses. 38, 39 In all 4 drugs, the predicted exit rate was significantly lower for patients randomized to the higher doses for LEV-XR and PGB and to both doses for LCM and ESL compared with the historical controls. The most frequent AEs associated with LEV-XR included somnolence, headaches, and convulsions and did not differ between the 2 doses. For PGB, the most frequent AEs were similar to those reported in the add-on PGB trials previously described. [6] [7] [8] For LCM, the most common AEs were dizziness, headache, nausea, convulsions, somnolence, and fatigue, most of which were of mild to moderate severity and comparable between the 2 doses; dizziness occurred more in the 400-mg group. For ESL, the most frequent AEs included dizziness, headache, fatigue, somnolence, nausea, and nasopharyngitis and were dose dependent. 
Conclusions
ESL is possibly effective as monotherapy for TRAFE (2 Class III studies). Evidence is insufficient to determine
Recommendations
Eslicarbazepine use may be considered to decrease seizure frequency as monotherapy for TRAFE (Level C).
Data are insufficient to recommend the use of second-and the other third-generation AEDs as monotherapy in TRAFE (Level U). 
Lamotrigine
LTG to treat TR GTC at several doses (depending on age and type of additional AED used) were compared with placebo in 1 Class II study with patients aged 2-55 years. 40 Twelve-week median percent reduction of GTC seizure frequency and responder rates were significantly higher for patients randomized to LTG. The most common LTG-related AEs included dizziness, somnolence, and nausea.
A second Class II study e1 demonstrated significant differences in median percent decrease from baseline in GTC seizures favoring LTG during both escalation and maintenance periods. AEs leading to drug discontinuation were rare. No rashes were reported.
Similar findings were obtained in a Class I study that included adolescents and adults using extended-release LTG (LTG-XR). e2 Those on LTG-XR experienced a significantly greater median percent reduction in weekly GTC seizure frequency and had a higher responder rate. Nausea, vomiting, and diplopia were the most frequent AEs related to LTG-XR.
Conclusion
Both LTG-XR and immediate-release LTG are probably effective as add-on therapy for TR GTC seizures (1 Class I study for LTG-XR; 2 Class II studies for immediate-release LTG).
Levetiracetam
Two Class I studies compared 3,000 mg/d LEV and placebo in TR GE. One study included patients aged 4-65 years. e3 LEV demonstrated significantly greater responder rates and GTC-free frequency. The second study assessed adolescents and adults with juvenile myoclonic epilepsy (JME) or juvenile absence epilepsy. e4 Compared with those on placebo, significantly more patients on LEV had a >50% reduction in the number of days per week with myoclonic seizures, became free of myoclonic seizures, and became free of all seizure types. In the first study, more patients on placebo discontinued therapy because of AEs, but irritability, fatigue, somnolence, and headache occurred in patients on LEV. Somnolence and neck pain were the only 2 AEs seen with greater frequency among patients on LEV in the second study.
Conclusions
LEV is probably effective as add-on therapy for TR GE presenting with GTC seizures (1 Class I study). LEV is probably effective as add-on therapy for TR JME and juvenile absence seizures (1 Class I study). The data from these studies could be generalized to all patients with TR GE; however, the requirement of at least 3 GTC seizures during the 8-week baseline phase in the first study pertains to patients with more severe GE.
Clinical context
Only high LEV doses were used.
Recommendations
For add-on therapy for GE, immediate-release and LTG-XR use should be considered as add-on therapy to decrease seizure frequency in treating adults with TR GTC seizures secondary to GE (Level B). Levetiracetam use should be considered to decrease seizure frequency as add-on therapy for TR GTC seizures and for TR JME (Level B).
Clinical context
Because the seizures of most patients with idiopathic GE are easily controlled with appropriate medication, presentation of TR epilepsy is rare. It is unclear how results in this population would translate to patients with similar syndromes but with nonrefractory disease.
For adult and pediatric patients with LGS, are these AEDs effective as adjunctive therapy in reducing seizure frequency (compared with no adjunctive therapy)?
In the 2004 guidelines, FBM, LTG, and TPM were found to be effective in treating LGS. Since then, studies of CLB and RFN have been published.
Clobazam
CLB efficacy was compared with placebo in 2 Class II studies. Three daily doses (0.25, 0.5, and 1 mg/kg) were examined. e5,e6 Relative to baseline seizure frequency, weekly drop seizure rates were significantly reduced with all 3 doses, with greater reduction in the high-dose group. Nondrop seizures were also reduced in a dose dependent manner. The most common AEs included somnolence, lethargy, sedation, salivary hypersecretion, constipation, aggression, hypomania, and insomnia. Lethargy, aggression, ataxia, fatigue, and aggression were the most frequent AEs leading to drug discontinuation.
Conclusion
CLB is probably effective as add-on therapy for LGS (2 Class II studies).
Rufinamide
Two Class I studies compared RFN with placebo in children and young adults.
e7,e8 Doses up to 45 mg/kg/d were examined. Patients randomized to RFN experienced significantly greater median percent reductions in total seizure frequency and frequency of drop attacks and greater median percent change in tonic-atonic seizures. Common AEs included somnolence, vomiting, and decreased appetite.
Conclusion
RFN is established as effective as add-on therapy for LGS (2 Class I studies).
Recommendations
For LGS, RFN use should be considered established as effective to decrease seizure frequency as add-on therapy (Level A), and CLB use should be considered (Level B). 
Levetiracetam
Two Class I studies compared LEV with placebo. e9,e10 The first study e9 included children and young adolescents (aged 4-16 years) and a target dose of 60 mg/kg/d. LEV had significantly greater responder rates per week and median reductions in seizure frequency per week. LEV was associated with more frequent AEs, which included somnolence, accidental injury, vomiting, anorexia, rhinitis, hostility, increased cough, pharyngitis, and nervousness. However, AE-related withdrawal from the study was higher among children randomized to placebo.
The second Class I study randomized children aged 1 month to < 4 years to placebo or LEV at a dose of 40 mg/kg/d (if aged < 6 months) or 50 mg/kg/d (if aged ≥ 6 months). e10 Children randomized to LEV had a significantly greater responder rate in average daily seizure frequency and greater median percent reduction from baseline. The most frequently reported LEV-related AEs included somnolence and irritability.
Conclusions
LEV is probably effective as add-on therapy for TR focal epilepsy in children and adolescents (1 Class I study).
Moreover, LEV is probably effective as add-on therapy in TR focal epilepsy in infants and children aged < 4 years (1 Class I study).
Oxcarbazepine
One Class I study of children aged 1 month to < 4 years compared 2 doses of OXC (10 mg/kg/d and 60 mg/kg/d). e11 The primary outcome was absolute change in the frequency of focal seizures per 24 hours during 3 days of continuous treatment-phase video electroencephalography compared with baseline seizure frequency. Children on the higher OXC dose experienced a significantly greater seizure frequency reduction and a greater median percent reduction in seizure frequency per 24 hours than those on the low dose. Children in the high-dose group also experienced more frequent AEs, including somnolence, ataxia, and vomiting.
Conclusion
OXC is probably effective as add-on therapy in infants and young children with TR focal epilepsy (1 Class I study). Given the study's short duration, however, generalizability may be limited.
Zonisamide
One Class I study of children and adolescents aged 6-17 years compared 8 mg/kg/d ZNS to placebo. e12 The 12-week responder rate was significantly higher for the patients randomized to ZNS. The incidence of AEs did not differ between the 2 groups, although AEs leading to withdrawal occurred more often in the placebo group. The AEs reported with a higher frequency in the ZNS group included decreased appetite, decreased weight, somnolence, vomiting, and diarrhea.
Conclusion
ZNS is probably effective as add-on therapy for TR focal epilepsy in children and adolescents (1 Class I study). Data are unavailable on the efficacy of CLB, ESL, LCM, PER, PGB, RFN, TGB, or VGB as add-on therapy for this group.
Recommendations
For add-on therapy for TR focal epilepsy, LEV use should be considered to decrease seizure frequency (Level B for ages 1 month to 16 years); ZNS use should be considered to decrease seizure frequency (Level B for ages 6-17 years) and OXC use should be considered to decrease seizure frequency (Level B for ages 1 month to 4 years).
Data are unavailable on the efficacy of CLB, ESL, LCM, PER, PGB, RFN, TGB, or VGB as add-on therapy for the treatment of these children or adolescents (Level U).
Clinical context
A pharmacokinetic: pharmacodynamic analysis performed comparing adults with children receiving approved AEDs showed similar seizure reduction for the 2 groups when serum concentrations were similar. On the basis of these data, the FDA determined that efficacy of AEDs for focal seizures in adults can be extrapolated downward to children 4 years of age.
e13,e14
For pediatric patients with TR focal epilepsy, are these AEDs effective as monotherapy in reducing seizure frequency? No data are available to answer this question. Thus, no recommendation is made.
Have new serious AEs been identified in the AEDs evaluated in the 2004 guideline?
No new serious AEs have been identified.
RECOMMENDATIONS FOR FUTURE RESEARCH
Head-to-head trials are lacking on newer AEDs in patients with TR focal epilepsy and TR GE. In studies of new-onset epilepsy, higher-dose forced titrations led to higher AE rates. Future studies should use doses commonly used in clinical practice and use flexible-dosing regimens. Finally, there is a lack of placebo-controlled and head-to-head trials of newer AEDs in pediatric patients.
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